|OnControl coaxial biopsy tray--Courtesy of Vidacare|
The deal: Teleflex grabs Vidacare
The price tag: $262.5 million
Why it matters: This acquisition, announced last October, allows Teleflex ($TFX) to take a major step toward growing its vascular access product portfolio into new areas. The company bills itself as being a provider of specialty medical devices for critical care and surgery. Its Vidacare deal gives it a whole new slew of products that help access the inner bone for a variety of medical, diagnostic and therapeutic options covering vascular access, emergency medicine, oncology and spinal surgery. Some key products Teleflex had its eye on: the EZ-IO Intraosseous Vascular Access System and the OnControl Bone Marrow System. At the time, Teleflex Chairman, President and CEO Benson Smith referred to Vidacare as "an industry leader with a high gross margin profile" and "a defining technology." And now Teleflex gets to reap the benefits.
Teleflex will grab Vidacare for $262.5M to boost vascular access device options
Teleflex grabs Israel startup with next-gen microlaparoscopy tech
Teleflex snags CE mark for balloon catheter